Profile of temsirolimus in the treatment of advanced renal cell carcinoma

Abstract

Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.

Keywords:

• renal cell cancer
• nonclear cell renal cancer
• temsirolimus
• first-line therapy
• overall survival
• nephrectomy

Disclosure

The authors declare no conflicts of interest.